**CERTIFICATE OF ANALYSIS**

**CERTIFICATE No:**  CAN/2015-16/XYZ

|  |  |  |  |
| --- | --- | --- | --- |
| **PRODUCT** | ANGILOCK PLUS 50/12.5 TABLETS | | REF. NO: NDQD201507029 |
| **DATE RECEIVED:** 17.07.2015 | **LABEL CLAIM:** | Each film coated tablet contains; Losartan Potassium USP 50 mg and Hydrochlorothiazide BP 12.5 mg. | |
| **BATCH NO.:** 506 004 | **PRESENTATION:** | Light yellow coloured, circular shaped, biconvex faced tablets, embossed 'SOO5' on one face, but plain on the other, packed in aluminium foil blister strips in a box carrying 3 strips of 10 tablets each. | |
| **MGF. DATE:** Jun. 2015 | **MANUFACTURER:** | SQUARE Pharmaceuticals Ltd. | |
| **EXP. DATE:** May 2017 | **ADDRESS:** | Dhaka Unit, Kaliakoir, Gazipur, BANGLADESH. | |
| **CLIENT REF NO:** | **CLIENT:** | Ace Pharmaceuticals Ltd P.O BOX 29787-00202 Nairobi KENYA | |
|  | **TEST(S) REQUESTED:** | Uniformity of Weight, Identification, Dissolution, Assay | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **TEST** | **METHOD** | **COMPEDIA** | **SPECIFICATION** | **DETERMINED** | **REMARKS** |
| **Uniformity of Weight** | Weight | B.P. 2012 Vol .V App XII C | NMT 2 tablets deviate by more than 7.5% from mean weight | None Deviates | **COMPLIES** |
| **Identification** | HPLC:HPLC | U.S.P. 38 N.F. 33 Vol.2 Page 4156 | RT of the component peaks in the assay sample preparation corresponds to those in the assay standard preparation | Super-imposable peaks at RT | **COMPLIES** |
| **Identification** | HPLC:HPLC | U.S.P. 38 N.F. 33 Vol.2 Page 4156 | RT of the component peaks in the assay sample preparation corresponds to those in the assay standard preparation | 3.7 and 6.9 +/- 10% min. present in both the assay sample and standard preparations | **COMPLIES** |
| **Dissolution** | HPLC:HPLC | U.S.P. 38 N.F. 33 Vol.2 Page 4156:U.S.P. 38 N.F. 33 Vol.2 Page 4156 | Hydrochlorthiazide - No tablet less than 80% Losartan Potassium - No tablet less than 90% [n=6] | Hydrochlorthiazide; 99.5% (RSD = 1.2%; n = 6) | **COMPLIES:COMPLIES** |
| **Dissolution** | HPLC:HPLC | U.S.P. 38 N.F. 33 Vol.2 Page 4156:U.S.P. 38 N.F. 33 Vol.2 Page 4156 | Hydrochlorthiazide - No tablet less than 80% Losartan Potassium - No tablet less than 90% [n=6] | Losartan; 100.5% (RSD = 1.2%; n = 6) | **COMPLIES:COMPLIES** |
| **Assay** | HPLC | U.S.P. 38 N.F. 33 Vol.2 Page 4156 | 95.0 - 105.0% | Hydrochlorthiazide; 96.0% (RSD = 0.3%; n = 9) | **COMPLIES:COMPLIES** |
| **Assay** | HPLC | U.S.P. 38 N.F. 33 Vol.2 Page 4156 | 95.0 - 105.0% | Losartan; 98.9% (RSD = 0.7%; n = 9) | **COMPLIES:COMPLIES** |

**CONCLUSION:** The product complies with the specifications for the tests performed.

|  |  |  |  |
| --- | --- | --- | --- |
| ANALYST: | DR. K. BOTA |  | DATE:23-10-2015 |
| REVIEWER: | DR. G. WANG’ANG’A |  | DATE:28-10-2015 |
| ANALYST: | NICHOLAS MWAURA |  | DATE:11-03-2015 |
| DIRECTOR: | HEZEKIAH CHEPKWONY |  | DATE:11-06-2015 |